HEIDELBERG, Germany, February 06, 2025 / Biotech Newswire / --

德国海德堡，2025年2月6日/生物技术通讯社/--

German independent research institute

德国独立研究所

BioMed X

生物医学X

announces the successful completion of its oncology research project in partnership with Merck. The data generated by this project has been acquired by Merck for further development, potentially leading to new therapeutic approaches in precision oncology.

宣布与默克公司合作成功完成其肿瘤学研究项目。该项目产生的数据已由默克公司获得以供进一步开发，可能会导致精准肿瘤学的新治疗方法。

Launched in August 2022, the collaboration aimed to unravel the mechanisms behind the formation, propagation, and impact of ecDNA in cancer cells using state-of-the-art single-cell screening and spatial technologies. The project was led by Dr. Alexandros Drainas, winner of the BioMed X Innovation Boot Camp, and mentored by Dr.

。该项目由AlexandrosDrainas博士领导，他是BioMed X创新训练营的获胜者，并由Dr。

Sebastian M. Waszak, Assistant Professor at EPFL, Lausanne, Switzerland. Industry guidance provided by Dr. Balca Mardin, Head of Target Discovery & Research at Merck..

SebastianM.Waszak，瑞士洛桑EPFL助理教授。默克公司目标发现与研究负责人Balca Mardin博士提供的行业指导。。

The multidisciplinary BioMed X team made significant strides in understanding ecDNA biology by addressing fundamental questions, such as:

多学科生物医学X团队通过解决以下基本问题，在理解ecDNA生物学方面取得了重大进展：

The team’s research identified genes that may reduce ecDNA abundance in cancer cells. Additionally, Team EDC developed advanced spatial technologies to explore how ecDNA localization affects cancer cell adaptability. The project was completed earlier than expected thanks to the promising and unexpected results achieved by the team.

该团队的研究确定了可能降低癌细胞中ecDNA丰度的基因。此外，EDC团队开发了先进的空间技术，以探索ecDNA定位如何影响癌细胞的适应性。由于团队取得了令人鼓舞和意想不到的成果，该项目比预期提前完成。

These early findings may offer promising strategies for mitigating cancer heterogeneity and reducing the mechanisms driving therapeutic resistance, potentially improving the efficacy of existing treatments..

这些早期发现可能为减轻癌症异质性和减少驱动治疗抵抗的机制提供有希望的策略，从而可能提高现有治疗的疗效。。

Dr.

博士。

Thomas Rückle

托马斯·吕克尔

,

,

Senior Vice President Research at the BioMed X Institute,

生物医学X研究所高级副总裁，

emphasized the importance of this achievement: “Our collaboration with Merck has once again demonstrated the power of combining academic curiosity with industrial expertise. The knowledge gained from this project not only advances cancer research but also showcases the potential of ecDNA-targeted therapies.

强调了这一成就的重要性：“我们与默克公司的合作再次证明了将学术好奇心与工业专业知识相结合的力量。从这个项目中获得的知识不仅推进了癌症研究，而且展示了ecDNA靶向治疗的潜力。

We look forward to continuing our successful partnership with Merck and our joint journey towards a deeper understanding of complex life-threatening diseases.”.

我们期待着继续与默克公司的成功合作，以及我们对威胁生命的复杂疾病的深入了解。”。

For high resolution please click the image.

要获得高分辨率，请单击图像。

About

关于

BioMed X

生物医学X

BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. We operate at the interface between academia and industry, performing biomedical research and drug discovery & development in the fields of oncology, immunology, neuroscience, platform technologies, and artificial intelligence..

BioMed X是一家独立的研究机构，在德国海德堡、康涅狄格州纽黑文、康涅狄格州里奇菲尔德的XSeed实验室以及全球合作伙伴网络都设有分支机构。我们在学术界和工业界的界面上运作，在肿瘤学、免疫学、神经科学、平台技术和人工智能领域进行生物医学研究和药物发现与开发。。

All our research projects are supported by leading pharmaceutical companies and conducted by early-career scientists recruited from the best schools around the world. The combination of global crowdsourcing with local incubation of the best research talents and ideas allows us to solve the biggest challenges in biomedical research..

我们所有的研究项目都得到了领先制药公司的支持，并由从世界各地最好的学校招募的早期职业科学家进行。全球众包与最佳研究人才和想法的本地孵化相结合，使我们能够解决生物医学研究中最大的挑战。。

We stand for free, creative, and curiosity-driven research combined with a solid validation of results, timelines, and deliverables. We serve a large purpose in advancing translational biomedicine by leveraging synergies and fostering cross-pollination across disciplines.

我们主张自由、创造性和好奇心驱动的研究，并结合对结果、时间表和可交付成果的可靠验证。我们通过利用协同作用和促进跨学科的交叉授粉来推进转化生物医学。

Contact

联系人

BioMed X

生物医学X

Maria Morganti

玛丽亚 摩根蒂

Head of Marketing

市场营销主管

+49 155 66963726

+49 155 66963726

This email address is being protected from spambots. You need JavaScript enabled to view it.

此电子邮件地址受到垃圾邮件的保护。。

Keywords: International Cooperation; Academies and Institutes; Drug Discovery; Biomedical Research; Academies and Institutes; Early Detection of Cancer; Genetic Techniques; Germany; BioMed X Institute; Merck; Extrachromosomal DNA (ecDNA); Cancer research; Oncology; Precision oncology; Single-cell screening; Spatial technologies; Dr.

关键词：国际合作；学院和研究所；药物发现；生物医学研究；学院和研究所；早期发现癌症；遗传技术；德国；；默克公司；染色体外DNA（ecDNA）；癌症研究；肿瘤学；精准肿瘤学；单细胞筛选；空间技术；博士。

Alexandros Drainas; Dr. Sebastian M. Waszak; Dr. Balca Mardin; Target Discovery & Research; Cancer cell adaptability; Cancer heterogeneity; Therapeutic resistance; ecDNA-targeted therapies; Drug discovery & development; Translational biomedicine;.

亚历山德罗斯·德莱纳斯；Sebastian M.Waszak博士；Balca Mardin博士；目标发现与研究；癌细胞适应性；癌症异质性；治疗抵抗；ecDNA靶向治疗；药物发现与开发；转化生物医学；。

Source: Biotech Newswire

资料来源：Biotech Newswire